The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is a progressive liver disease with ever-growing incidence in the industrialized world. It starts with the simple accumulation of lipids in the hepatocyte and can progress to the more severe nonalcoholic steatohepatitis (NASH), which is associated with inflammation, fibrosis, and cirrhosis. There is increasing awareness that reactive oxygen species and electrophiles are implicated in the pathogenesis of NASH. Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a positive regulator of the expression of a battery of genes involved in the protection against oxidative/electrophilic stress. In rodents, Nrf2 is also known to participate in hepatic fatty acid metabolism, as a negative regulator of genes that promote hepatosteatosis. We review relevant evidence in the literature that these two mechanisms may contribute to the protective role of Nrf2 in the development of hepatic steatosis and in the progression to steatohepatitis, particularly in young animals. We propose that age may be a key to explain contradictory findings in the literature. In summary, Nrf2 mediates the crosstalk between lipid metabolism and antioxidant defense mechanisms in experimental models of NAFLD, and the nutritional or pharmacological induction of Nrf2 represents a promising potential new strategy for its prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Rushmore, T. H., Morton, M. R., & Pickett, C. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99004-6 · Cited by 1,464
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680
Regulation of lipid stores and metabolism by lipophagy
Liu, K., & Czaja, M. J. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.63 · Cited by 542
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
Research works printed but not linked: 78
- 10.1007/978-1-4419-7107-4_10 · DOI
- 10.1016/j.freeradbiomed.2013.08.174 · DOI · Paper page
- 1960, Journal of Lipid Research, 1, 326, 10.1016/S0022-2275(20)39055-6 · doi:10.1016/s0022-2275(20)39055-6
- 2013, World Journal of Hepatology, 5, 550, 10.4254/wjh.v5.i10.550 · DOI · Paper page
- 10.1074/jbc.m109.026203 · DOI · Paper page
- 10.1016/j.jhep.2010.06.044 · DOI · Paper page
- 10.1016/j.plipres.2012.10.004 · DOI · Paper page
- 10.1001/jama.287.3.356 · DOI · Paper page
- 10.1089/met.2008.0070 · DOI · Paper page
- 10.1111/j.1464-5491.2006.01858.x · DOI · Paper page
- 10.1016/j.bpg.2014.07.008 · DOI · Paper page
- 10.1002/hep.510270601 · DOI · Paper page
- 10.1155/2013/327167 · DOI · Paper page
- 10.1586/egh.11.4 · DOI · Paper page
- 10.1111/liv.12523 · DOI
- 10.1016/j.taap.2010.03.016 · DOI · Paper page
- 10.1093/carcin/bgp100 · DOI · Paper page
- 10.1016/j.jprot.2010.03.018 · DOI · Paper page
- 10.1124/jpet.107.135822 · DOI · Paper page
- 10.1111/j.1440-1746.2012.07180.x · DOI
- 10.1016/j.taap.2012.09.014 · DOI
- 10.1016/j.ejphar.2009.08.022 · DOI · Paper page
- 10.1152/ajpgi.00322.2010 · DOI · Paper page
- 10.1074/jbc.m110.176545 · DOI
- 10.1016/j.freeradbiomed.2011.11.012 · DOI
- 10.1007/s00535-012-0552-9 · DOI
- 10.1124/mol.112.084269 · DOI
- 10.1016/j.freeradbiomed.2014.03.025 · DOI · Paper page
- 10.1021/tx050217c · DOI · Paper page
- 10.1073/pnas.94.10.5361 · DOI · Paper page
- 10.1146/annurev.pharmtox.43.100901.140229 · DOI · Paper page
- 10.1074/jbc.m211558200 · DOI · Paper page
- 10.1016/j.freeradbiomed.2011.11.038 · DOI · Paper page
- 10.1016/j.biocel.2005.09.018 · DOI · Paper page
- 10.1074/jbc.m412081200 · DOI · Paper page
- 10.1016/j.tibs.2014.02.002 · DOI · Paper page
- 10.1016/j.mrrev.2007.11.006 · DOI · Paper page
- 10.1016/j.jhep.2010.11.005 · DOI · Paper page
- 10.1038/ncb2021 · DOI · Paper page
- 10.1038/embor.2011.246 · DOI
- 10.1242/bio.20134853 · DOI · Paper page
- 10.1042/BJ20130863 · DOI · Paper page
- 10.1080/01926230701311344 · DOI · Paper page
- 10.1016/j.taap.2010.01.013 · DOI · Paper page
- 10.1155/2013/305861 · DOI
- 10.1016/j.taap.2011.07.019 · DOI
- 10.1038/labinvest.2008.75 · DOI · Paper page
- 10.1016/j.jhep.2013.09.004 · DOI
- 1991, The Biochemical Journal, 277, 723, 10.1042/bj2770723 · DOI
- 10.1002/hep.22473 · DOI
- 10.1007/s11745-010-3492-2 · DOI
- 10.1038/sj.emboj.7601950 · DOI · Paper page
- 10.2119/molmed.2013.00027 · DOI
- 10.1111/acel.12128 · DOI · Paper page
- 10.1073/pnas.0400282101 · DOI · Paper page
- 10.1007/s10522-006-9033-y · DOI · Paper page
- 10.1016/S0891-5849(03)00073-X · DOI
- 10.1161/circresaha.108.188771 · DOI · Paper page
- 10.1007/s11892-013-0372-1 · DOI
- 10.1124/dmd.110.035006 · DOI · Paper page
- 10.1152/ajpgi.00296.2009 · DOI · Paper page
- 10.1016/j.freeradbiomed.2009.11.007 · DOI · Paper page
- 10.1186/1476-511x-12-165 · DOI
- 10.1007/s00535-012-0659-z · DOI
- 2004, Molecular Cancer Therapeutics, 3, 885, 10.1158/1535-7163.885.3.7 · DOI · Paper page
- 10.1021/jm980424s · DOI · Paper page
- 10.1073/pnas.051618798 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-4539 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-1906 · DOI · Paper page
- 10.1523/jneurosci.1683-07.2007 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-3823 · DOI · Paper page
- 2012, Clinical Pharmacology & Therapeutics, 92, 340, 10.1038/clpt.2012.110 · DOI · Paper page
- 10.1016/j.freeradbiomed.2005.08.043 · DOI · Paper page
- 10.1016/S0140-6736(08)61619-0 · DOI · Paper page
- 10.1158/1535-7163.MCT-06-0516 · DOI · Paper page
- 10.5483/BMBRep.2005.38.2.167 · DOI
- 10.1016/j.freeradbiomed.2011.09.017 · DOI
- 10.3390/ijms141121240 · DOI · Paper page
Cited by
Arroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03003-w · Cited by 518
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver
Ramos-Tovar, E., & Muriel, P. (2020) · Antioxidants · doi:10.3390/antiox9121279 · Cited by 340
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
Metadata
- Authors
- Chambel, S. S., Santos-Gonçalves, A., & Duarte, T. L.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-10
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1554837601
- Cited by
- 191
- References
- 9
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Fundação para a Ciência e a Tecnologia (FCOMP-01-0124-FEDER-028447)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism. https://app.cochat.ai/papers/10.1155/2015/597134
- The paper
- Chambel, S. S., Santos-Gonçalves, A., & Duarte, T. L. (2015). The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism. BioMed Research International. https://doi.org/10.1155/2015/597134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.